Lv3
312 积分 2025-03-15 加入
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
17小时前
已完结
Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study
17小时前
求助中
New Method of Genome Editing Derived From CRISPR/Cas9
7天前
已完结
Mirdametinib approval for neurofibromatosis type 1 with inoperable plexiform neurofibromas: the journey of MEK inhibitors
2个月前
已完结
Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels
2个月前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2个月前
已完结
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
2个月前
已完结
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC
2个月前
已完结
Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis
2个月前
已完结
皖公网安备34019202002308
